Trinity Biotech Plc Stock Performance
| TRIB Stock | USD 0.77 0.02 2.53% |
On a scale of 0 to 100, Trinity Biotech holds a performance score of 2. The entity has a beta of 1.24, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Trinity Biotech will likely underperform. Please check Trinity Biotech's sortino ratio, skewness, price action indicator, as well as the relationship between the potential upside and rate of daily change , to make a quick decision on whether Trinity Biotech's existing price patterns will revert.
Risk-Adjusted Performance
Weak
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Trinity Biotech plc are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Despite somewhat unfluctuating forward indicators, Trinity Biotech sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
Last Split Factor 1:5 | Dividend Date 2015-07-01 | Ex Dividend Date 2015-06-05 | Last Split Date 2024-02-23 |
1 | Trinity Industries Valuation Check After Its Latest Dividend Increase and Ongoing Shareholder Payout Streak | 12/05/2025 |
2 | Trinity Investments Expands European Platform With Acquisition of The Hoxton, Poblenou in Barcelona | 12/18/2025 |
3 | Im obsessed with beauty tech these are the microcurrent devices that actually work | 01/26/2026 |
4 | Disposition of 17800 shares by Robert R Mccormick Tribune Foundation of Trinity Biotech at 51.9396 subject to Rule 16b-3 | 01/27/2026 |
5 | Cameron Smith Forward to join Wakefield Trinity on long-term deal from 2027 | 01/29/2026 |
6 | Trinity One Metals Closes Acquisition of Silver-1 Historic Silver Mine in Southern Ecuador | 02/04/2026 |
7 | The UKs most beautiful city branded Venice of England that blows tourists away | 02/06/2026 |
8 | Americore Resources Is Pleased to Provide a Corporate Update | 02/09/2026 |
9 | California housing affordability improves from third-quarter 2025 and a year ago, C.A.R. reports | 02/10/2026 |
10 | Trinity Ranked Top Health Sciences Consulting Firm in 2026 Vault Consulting Rankings | 02/11/2026 |
11 | Why Is Trinity Stock Rocketing Higher Today | 02/12/2026 |
12 | Bell Potter names 3 sold-off ASX 200 shares to buy today | 02/13/2026 |
| Begin Period Cash Flow | 3.7 M | |
| Total Cashflows From Investing Activities | -23 M |
Trinity Biotech Relative Risk vs. Return Landscape
If you would invest 82.00 in Trinity Biotech plc on November 17, 2025 and sell it today you would lose (5.00) from holding Trinity Biotech plc or give up 6.1% of portfolio value over 90 days. Trinity Biotech plc is currently generating 0.2213% in daily expected returns and assumes 8.4623% risk (volatility on return distribution) over the 90 days horizon. In different words, 76% of stocks are less volatile than Trinity, and 96% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Trinity Biotech Target Price Odds to finish over Current Price
The tendency of Trinity Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.77 | 90 days | 0.77 | about 80.13 |
Based on a normal probability distribution, the odds of Trinity Biotech to move above the current price in 90 days from now is about 80.13 (This Trinity Biotech plc probability density function shows the probability of Trinity Stock to fall within a particular range of prices over 90 days) .
Trinity Biotech Price Density |
| Price |
Predictive Modules for Trinity Biotech
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Trinity Biotech plc. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Trinity Biotech Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Trinity Biotech is not an exception. The market had few large corrections towards the Trinity Biotech's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Trinity Biotech plc, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Trinity Biotech within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.08 | |
β | Beta against Dow Jones | 1.24 | |
σ | Overall volatility | 0.13 | |
Ir | Information ratio | -0.0073 |
Trinity Biotech Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Trinity Biotech for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Trinity Biotech plc can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Trinity Biotech plc had very high historical volatility over the last 90 days | |
| Trinity Biotech plc has some characteristics of a very speculative penny stock | |
| Trinity Biotech plc has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 61.55 M. Net Loss for the year was (31.79 M) with profit before overhead, payroll, taxes, and interest of 21.44 M. | |
| Trinity Biotech plc currently holds about 10.01 M in cash with (4.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.41. | |
| Trinity Biotech plc has a poor financial position based on the latest SEC disclosures | |
| Roughly 66.0% of the company shares are owned by institutional investors | |
| Latest headline from fool.com.au: Bell Potter names 3 sold-off ASX 200 shares to buy today |
Trinity Biotech Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Trinity Stock often depends not only on the future outlook of the current and potential Trinity Biotech's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Trinity Biotech's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 18 M | |
| Cash And Short Term Investments | 5.2 M |
Trinity Biotech Fundamentals Growth
Trinity Stock prices reflect investors' perceptions of the future prospects and financial health of Trinity Biotech, and Trinity Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Trinity Stock performance.
| Return On Equity | -19.13 | ||||
| Return On Asset | -0.11 | ||||
| Profit Margin | (0.52) % | ||||
| Operating Margin | (0.43) % | ||||
| Current Valuation | 125.42 M | ||||
| Shares Outstanding | 18.63 M | ||||
| Price To Earning | 31.00 X | ||||
| Price To Book | 5.11 X | ||||
| Price To Sales | 0.30 X | ||||
| Revenue | 61.55 M | ||||
| Gross Profit | 21.44 M | ||||
| EBITDA | (16.91 M) | ||||
| Net Income | (31.79 M) | ||||
| Cash And Equivalents | 10.01 M | ||||
| Cash Per Share | 0.41 X | ||||
| Total Debt | 100.76 M | ||||
| Current Ratio | 3.66 X | ||||
| Book Value Per Share | (1.96) X | ||||
| Cash Flow From Operations | (4.19 M) | ||||
| Earnings Per Share | (1.80) X | ||||
| Market Capitalization | 15.89 M | ||||
| Total Asset | 103.29 M | ||||
| Retained Earnings | (79.12 M) | ||||
| Working Capital | 9.03 M | ||||
| Current Asset | 151 M | ||||
| Current Liabilities | 21 M | ||||
About Trinity Biotech Performance
By analyzing Trinity Biotech's fundamental ratios, stakeholders can gain valuable insights into Trinity Biotech's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Trinity Biotech has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Trinity Biotech has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 158.66 | 163.83 | |
| Return On Tangible Assets | (0.70) | (0.67) | |
| Return On Capital Employed | (0.27) | (0.25) | |
| Return On Assets | (0.28) | (0.26) | |
| Return On Equity | 0.81 | 0.85 |
Things to note about Trinity Biotech plc performance evaluation
Checking the ongoing alerts about Trinity Biotech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Trinity Biotech plc help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Trinity Biotech plc had very high historical volatility over the last 90 days | |
| Trinity Biotech plc has some characteristics of a very speculative penny stock | |
| Trinity Biotech plc has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 61.55 M. Net Loss for the year was (31.79 M) with profit before overhead, payroll, taxes, and interest of 21.44 M. | |
| Trinity Biotech plc currently holds about 10.01 M in cash with (4.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.41. | |
| Trinity Biotech plc has a poor financial position based on the latest SEC disclosures | |
| Roughly 66.0% of the company shares are owned by institutional investors | |
| Latest headline from fool.com.au: Bell Potter names 3 sold-off ASX 200 shares to buy today |
- Analyzing Trinity Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Trinity Biotech's stock is overvalued or undervalued compared to its peers.
- Examining Trinity Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Trinity Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Trinity Biotech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Trinity Biotech's stock. These opinions can provide insight into Trinity Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Trinity Stock analysis
When running Trinity Biotech's price analysis, check to measure Trinity Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Trinity Biotech is operating at the current time. Most of Trinity Biotech's value examination focuses on studying past and present price action to predict the probability of Trinity Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Trinity Biotech's price. Additionally, you may evaluate how the addition of Trinity Biotech to your portfolios can decrease your overall portfolio volatility.
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |